Sector News

Moderna, after firing newly hired CFO, finds replacement in PerkinElmer executive

August 21, 2022
Life sciences

Moderna has found a replacement for ousted CFO Jorge Gomez, announcing Wednesday that PerkinElmer executive James Mock will be its next finance chief.

The appointment of Mock comes several months after Moderna hired and then quickly fired Gomez from the role after it became known Gomez’ former employer, dental equipment manufacturer Dentsply Sirona, was investigating “certain financial reporting matters.”

Mock has served as CFO at PerkinElmer, a large life sciences and diagnostics firm, since 2018, overseeing several small acquisitions as well as a roughly $5.3 billion takeover of antibody and reagent provider BioLegend last year. On Aug. 1, PerkinElmer announced plans to divest its food and enterprise services division to a private equity firm for almost $2.5 billion.

Prior to PerkinElmer, Mock worked for nearly two decades at General Electric. READ MORE

By Ned Pagliarulo

Source: biopharmadive.com

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach